Novartis Sees OTCs As Crucial In Emerging – And Emerged – Global Markets
This article was originally published in The Tan Sheet
Executive Summary
Over-the-counter and generic drugs will benefit "disproportionately" compared with prescription drugs in emerging global markets, according to Novartis Head of Corporate Mergers & Acquisitions Nayan Gregory Parekh, PhD
You may also be interested in...
Novartis OTC Division Is “Fastest Growing” Among Industry Leaders – CEO
Novartis Consumer Health showed "strong performance" in 2006 with full year net sales of $7.53 billion, according to earnings results announced during a fourth-quarter and year-end call Jan. 18
Novartis OTC Division Is “Fastest Growing” Among Industry Leaders – CEO
Novartis Consumer Health showed "strong performance" in 2006 with full year net sales of $7.53 billion, according to earnings results announced during a fourth-quarter and year-end call Jan. 18
Novartis OTC Division Is “Fastest Growing” Among Industry Leaders – CEO
Novartis Consumer Health showed "strong performance" in 2006 with full year net sales of $7.53 billion, according to earnings results announced during a fourth-quarter and year-end call Jan. 18